ZA200108016B - Pyrazolobenzodiazephines as CDK2 inhibitors. - Google Patents

Pyrazolobenzodiazephines as CDK2 inhibitors.

Info

Publication number
ZA200108016B
ZA200108016B ZA200108016A ZA200108016A ZA200108016B ZA 200108016 B ZA200108016 B ZA 200108016B ZA 200108016 A ZA200108016 A ZA 200108016A ZA 200108016 A ZA200108016 A ZA 200108016A ZA 200108016 B ZA200108016 B ZA 200108016B
Authority
ZA
South Africa
Prior art keywords
pyrazolobenzodiazephines
cdk2 inhibitors
cdk2
inhibitors
Prior art date
Application number
ZA200108016A
Other languages
English (en)
Inventor
Qingjie Ding
Jin-Jun Liu
Vincent Stewart Madison
Giacomo Pizzolato
Chung-Chen Wei
Peter Michael Wovkulich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200108016B publication Critical patent/ZA200108016B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/22—Sulfur atoms
ZA200108016A 1999-04-21 2001-09-29 Pyrazolobenzodiazephines as CDK2 inhibitors. ZA200108016B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13037099P 1999-04-21 1999-04-21

Publications (1)

Publication Number Publication Date
ZA200108016B true ZA200108016B (en) 2003-03-26

Family

ID=22444382

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108016A ZA200108016B (en) 1999-04-21 2001-09-29 Pyrazolobenzodiazephines as CDK2 inhibitors.

Country Status (33)

Country Link
US (3) US6440959B1 (fr)
EP (1) EP1185529B1 (fr)
JP (1) JP3746680B2 (fr)
KR (1) KR100481757B1 (fr)
CN (2) CN1196703C (fr)
AR (1) AR023542A1 (fr)
AT (1) ATE279413T1 (fr)
AU (1) AU768667B2 (fr)
BR (1) BR0009887A (fr)
CA (1) CA2367704C (fr)
CO (1) CO5170444A1 (fr)
CZ (1) CZ20013738A3 (fr)
DE (1) DE60014893T2 (fr)
DK (1) DK1185529T3 (fr)
ES (1) ES2228522T3 (fr)
HK (1) HK1046278B (fr)
HR (1) HRP20010742A2 (fr)
HU (1) HUP0300318A3 (fr)
IL (1) IL145764A0 (fr)
JO (1) JO2248B1 (fr)
MA (1) MA26782A1 (fr)
NO (1) NO20015065D0 (fr)
NZ (1) NZ514523A (fr)
PE (1) PE20010054A1 (fr)
PL (1) PL200933B1 (fr)
PT (1) PT1185529E (fr)
RU (1) RU2249593C2 (fr)
SI (1) SI1185529T1 (fr)
TR (1) TR200103016T2 (fr)
TW (1) TW585866B (fr)
WO (1) WO2000064900A1 (fr)
YU (1) YU73101A (fr)
ZA (1) ZA200108016B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532463A (en) * 2001-11-13 2007-02-23 Dimensional Pharm Inc Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
WO2004076424A1 (fr) * 2003-02-27 2004-09-10 Abbott Laboratories Inhibiteurs de kinase heterocyclique
PL1802625T3 (pl) * 2004-10-13 2008-12-31 Hoffmann La Roche Dwupodstawione pirazolobenzodiazepiny użyteczne jako inhibitory CDK2 i angiogenezy oraz w leczeniu raka sutka, okrężnicy, płuca i gruczołu krokowego
EP1940410A1 (fr) * 2005-10-14 2008-07-09 F.Hoffmann-La Roche Ag Régime d'administration de la 5-(2-chlorophényl)-1,2-dihydro-7-fluoro-8-méthoxy-3-méthyl-pyrazolo [3,4.-b] [1, 4] benzodiazépine
EP2081921B1 (fr) 2006-07-10 2010-09-08 PAION UK Limited Sels de benzodiazépine et leurs formes polymorphes à action brève
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
EP2305647A1 (fr) * 2009-09-18 2011-04-06 PAION UK Limited Procédé de préparation d'ester de méthyle d'acide 3-[(4S)-8-bromo-1-méthyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazépine-4-yl] propionique ou son sulfonate de benzène, et composants utiles dans ce procédé
EP2450039A1 (fr) 2010-11-08 2012-05-09 PAION UK Ltd. Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)
EP3431087A1 (fr) * 2012-02-02 2019-01-23 Senex Biotechnology, Inc. Inhibiteurs sélectives de cdk8/cdk19 et procédés de leur utilisation dans les méthodes antimétastatiques et chimiopreventives pour cancer
CN103288830A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-5H-吡咯并[2,1-c][1,4]-苯并二氮杂卓的方法
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
WO2018083051A1 (fr) * 2016-11-01 2018-05-11 F. Hoffmann-La Roche Ag 1,3-dihydro -1,4-benzodiazépine-2-thiones pour le traitement de maladies liées au snc
CN108218868B (zh) 2016-12-13 2019-02-19 南京药捷安康生物科技有限公司 多激酶抑制剂化合物、其晶型及用途
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (fr) 2019-03-29 2020-10-08 Incyte Corporation Composés sulfonylamides utilisés comme inhibiteurs de la cdk2
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
KR20230008792A (ko) * 2020-05-08 2023-01-16 트랜스테라 사이언시즈 (난징), 인크. 항종양 화합물의 합성방법 및 그 중간체
WO2022113003A1 (fr) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Inhibiteurs de cdk
WO2022149057A1 (fr) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Inhibiteurs de cdk
JP2024517309A (ja) * 2021-05-10 2024-04-19 薬捷安康（南京）科技股▲分▼有限公司 マルチキナーゼ阻害剤の医薬組成物および使用
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024030399A2 (fr) * 2022-08-02 2024-02-08 Lab1636, Llc Utilisation d'un modulateur allostérique positif de gaba-a pour la réduction de l'hypersensibilité tactile

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266519C (fr) 1996-10-02 2007-01-23 Novartis Ag Derives de pyrimidine et procedes de preparation de ces derniers
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
ATE279413T1 (de) 2004-10-15
HK1046278A1 (en) 2003-01-03
NO20015065L (no) 2001-10-18
CN1348455A (zh) 2002-05-08
CN1603314A (zh) 2005-04-06
CO5170444A1 (es) 2002-06-27
EP1185529A1 (fr) 2002-03-13
HUP0300318A3 (en) 2004-11-29
AU768667B2 (en) 2003-12-18
YU73101A (sh) 2004-05-12
BR0009887A (pt) 2002-01-22
CA2367704A1 (fr) 2000-11-02
NO20015065D0 (no) 2001-10-18
US6440959B1 (en) 2002-08-27
PL354405A1 (en) 2004-01-12
MA26782A1 (fr) 2004-12-20
SI1185529T1 (en) 2005-02-28
EP1185529B1 (fr) 2004-10-13
RU2249593C2 (ru) 2005-04-10
DE60014893D1 (de) 2004-11-18
CN1196703C (zh) 2005-04-13
JP3746680B2 (ja) 2006-02-15
JO2248B1 (en) 2004-10-07
AU4748000A (en) 2000-11-10
CN1279029C (zh) 2006-10-11
AR023542A1 (es) 2002-09-04
KR20010112435A (ko) 2001-12-20
CA2367704C (fr) 2008-06-17
PL200933B1 (pl) 2009-02-27
DE60014893T2 (de) 2005-10-13
ES2228522T3 (es) 2005-04-16
JP2002543081A (ja) 2002-12-17
US20040198976A1 (en) 2004-10-07
US6838558B2 (en) 2005-01-04
DK1185529T3 (da) 2005-02-07
US20020183514A1 (en) 2002-12-05
WO2000064900A1 (fr) 2000-11-02
CZ20013738A3 (cs) 2002-08-14
TR200103016T2 (tr) 2002-04-22
HUP0300318A2 (hu) 2003-06-28
US6916923B2 (en) 2005-07-12
PT1185529E (pt) 2005-02-28
IL145764A0 (en) 2002-07-25
HRP20010742A2 (en) 2002-12-31
PE20010054A1 (es) 2001-02-07
TW585866B (en) 2004-05-01
HK1046278B (zh) 2005-08-12
NZ514523A (en) 2003-11-28
KR100481757B1 (ko) 2005-04-11

Similar Documents

Publication Publication Date Title
ZA200108016B (en) Pyrazolobenzodiazephines as CDK2 inhibitors.
ZA200109890B (en) Metalloprotease inhibitors.
ZA200108735B (en) Renin inhibitors.
IL148614A0 (en) Pteridinones as kinase inhibitors
GB9900416D0 (en) Inhibitors
ZA200206386B (en) Kinase inhibitors.
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
ZA991975B (en) Enzyme inhibitors.
ZA200200477B (en) 2-pyrazolin-5-ones.
HK1054384A1 (en) 4-Pyrimidinyl-n-acyl-l-phenylalanines.
HK1045299A1 (en) Cell proliferation inhibitors.
ZA200202537B (en) Pour-on-formulations.
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
ZA200203762B (en) 4-pyridinyl-IN-acyl-L-phenylalanines.
MXPA02005067A (es) Composicion inhibidora de la corrosion.
ZA200110053B (en) Factor via inhibitors.
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
EP1153022A4 (fr) Inhibiteurs de protease
GB9924522D0 (en) Enzyme inhibitors
GB0030284D0 (en) Enzyme inhibitors
MXPA01011285A (es) Derivados de tio-oxindol.
ZA200204581B (en) Nitro-sulfobenzamides.
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.
HK1031254A1 (en) Tachogragh.
HK1062445A1 (en) B-secretase inhibitor.